Answers are grounded in this paper and cite their sources.
Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies have emerged as promising therapeutic options for the treatment of chronic migraine. However, treatment response varies considerably among individuals, suggesting a potential role for genetic factors. This study aimed to identify genetic variants affecting the efficacy of anti-CGRP monoclonal antibody therapy in chronic migraine among the Han Chinese population in Taiwan to enhance treatment precision and to understand the genetic architecture of migraine.
No takes yet. Share an insight, caveat, or question.
An et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: